Service de Parasitologie- Mycologie, CHU Avicenne, Assistance Publique-Hôpitaux de Paris, 125 rue de Stalingrad, 93009, Bobigny Cedex, France.
Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France.
Malar J. 2019 Dec 16;18(1):422. doi: 10.1186/s12936-019-3067-5.
With less than one severe case per year in average, Plasmodium vivax is very rarely associated with severe imported malaria in France. Two cases of P. vivax severe malaria occurred in patients with no evident co-morbidity. Interestingly, both cases did not occur at the primary infection but during relapses.
Patient 1: A 27-year old male, born in Afghanistan and living in France since 2012, was admitted on August 2015 to the Avicenne hospital because of abdominal pain, intense headache, fever and hypotension. The patient was haemodynamically unstable despite 5 L of filling solution. A thin blood film showed P. vivax trophozoites within the red blood cells. To take care of the septic shock, the patient was given rapid fluid resuscitation, norepinephrine (0.5 mg/h), and intravenous artesunate. Nested polymerase chain reactions of the SSUrRNA gene were negative for Plasmodium falciparum but positive for P. vivax. The patient became apyretic in less than 24H and the parasitaemia was negative at the same time. Patient 2: A 24-year old male, born in Pakistan and living in France, was admitted on August 2016 because of fever, abdominal pain, headache, myalgia, and nausea. The last travel of the patient in a malaria endemic area occurred in 2013. A thin blood film showed P. vivax trophozoites within the red blood cells. The patient was treated orally by dihydroartemisinin-piperaquine and recovered rapidly. Nine months later, the patient returned to the hospital with a relapse of P. vivax malaria. The malaria episode was uncomplicated and the patient recovered rapidly. Three months later, the patient came back again with a third episode of P. vivax malaria. Following a rapid haemodynamic deterioration, the patient was transferred to the intensive care unit of the hospital. In all the patient received 10 L of filling solution to manage the septic shock. After 5 days of hospitalization and a specific treatment, the patient was discharged in good clinical conditions.
Clinicians should be aware of the potential severe complications associated with P. vivax in imported malaria, even though the primary infection is uncomplicated.
恶性疟原虫平均每年不到 1 例,非常罕见与法国的严重输入性疟疾相关。两例恶性疟原虫 vivax 严重疟疾发生在无明显合并症的患者中。有趣的是,这两例病例都不是在初次感染时发生的,而是在复发时发生的。
患者 1:一名 27 岁男性,出生于阿富汗,自 2012 年以来一直居住在法国,因腹痛、剧烈头痛、发热和低血压于 2015 年 8 月入住 Avicenne 医院。尽管输入了 5L 补液,患者仍存在血流动力学不稳定。薄血膜显示红细胞内有恶性疟原虫滋养体。为了治疗感染性休克,患者接受了快速补液、去甲肾上腺素(0.5mg/h)和静脉注射青蒿琥酯。SSUrRNA 基因的巢式聚合酶链反应对恶性疟原虫呈阴性,但对恶性疟原虫呈阳性。患者在不到 24 小时内退热,同时寄生虫血症转为阴性。患者 2:一名 24 岁男性,出生于巴基斯坦,居住在法国,因发热、腹痛、头痛、肌痛和恶心于 2016 年 8 月入院。患者最近一次在疟疾流行地区旅行发生在 2013 年。薄血膜显示红细胞内有恶性疟原虫滋养体。患者接受了双氢青蒿素-哌喹的口服治疗,并迅速康复。9 个月后,患者因恶性疟原虫疟疾复发再次入院。疟疾发作不复杂,患者迅速康复。3 个月后,患者再次出现第三例恶性疟原虫疟疾。由于血流动力学迅速恶化,患者被转至医院重症监护病房。在所有病例中,患者均接受了 10L 的补液以治疗感染性休克。经过 5 天的住院治疗和特异性治疗,患者在良好的临床条件下出院。
临床医生应意识到输入性疟疾中恶性疟原虫 vivax 可能出现严重并发症,即使初次感染不复杂。